Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
RESEARCH TOOLSreports
Holding GLUE?
Track your performance easily
GLUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.21 - $12.40
Previous CloseN/A
Volume283.19K
Average Volume (3M)1.49M
Market Cap
$353.88M
Enterprise Value$236.17M
Total Cash (Recent Filing)$6.00M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Mar 13, 2025EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding61,436,740
10 Day Avg. Volume1,190,042
30 Day Avg. Volume1,486,171
Standard Deviation0.28
R-Squared0.07
Alpha-0.00586
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.63
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue15.36
Enterprise Value/Gross Profit594.90
Enterprise Value/Ebitda-2.14
Forecast
1Y Price Target
$15.25Price Target Upside169.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Monte Rosa Therapeutics News
PremiumCompany Announcements
Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength
PremiumCompany Announcements
Monte Rosa Highlights Promising Results in Cancer StudyBulls Say, Bears Say
Bulls Say
Collaboration AgreementGLUE announced a collaborative agreement with Novartis to develop its first in class VAV1-degrader program MRT-6160.
Financial MilestonesGLUE will receive an upfront payment of $150M as well as total milestone payments of up to $2.1B.
Platform ValidationOverall, this collaboration agreement is viewed as additional robust validation of GLUE’s QuEEN MGD platform.
Bears Say
Clinical TrialsThe MRT-2359 update may be limited due to a small number of relevant patients, which may hinder understanding its activity in specific tumors.
PartnershipsThe decision to partner MRT-6160 limits material upside for the stock on the upcoming Phase 1 readout.
Pipeline DevelopmentThe remainder of GLUE's pipeline is at an early stage, with limited stock-moving clinical data expected from other projects.
---
Ownership Overview
22.89% Insiders
20.99% Mutual Funds
39.96% Other Institutional Investors
7.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GLUE FAQ
What was Monte Rosa Therapeutics’s price range in the past 12 months?
Monte Rosa Therapeutics lowest stock price was $3.21 and its highest was $12.40 in the past 12 months.
What is Monte Rosa Therapeutics’s market cap?
Monte Rosa Therapeutics’s market cap is $353.88M.
When is Monte Rosa Therapeutics’s upcoming earnings report date?
Monte Rosa Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 50 days.
How were Monte Rosa Therapeutics’s earnings last quarter?
Monte Rosa Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.475 by $0.185.
Is Monte Rosa Therapeutics overvalued?
According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued.
Does Monte Rosa Therapeutics pay dividends?
Monte Rosa Therapeutics does not currently pay dividends.
What is Monte Rosa Therapeutics’s EPS estimate?
Monte Rosa Therapeutics’s EPS estimate is 0.18.
How many shares outstanding does Monte Rosa Therapeutics have?
Monte Rosa Therapeutics has 61,436,740 shares outstanding.
What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?
Monte Rosa Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.475. Following the earnings report the stock price went up 0.847%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics?
Currently, no hedge funds are holding shares in GLUE
---
Monte Rosa Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.25 (169.43% Upside)
$15.25 (169.43% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.89%
12-Months-Change
Fundamentals
Return on Equity
-61.23%
Trailing 12-Months
Asset Growth
24.98%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
---
GLUE Stock 12 Month Forecast
Average Price Target
$15.25
▲(169.43% Upside)
Technical Analysis
Cabaletta Bio
―
BioAtla
―
Tango Therapeutics
―
Kiniksa Pharmaceuticals
―
RAPT Therapeutics
―
Allogene Therapeutics
―
Best Analysts Covering GLUE
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
+19.91%
reiterated a buy rating 2 months ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +19.91% per trade.
---